Aman's Global Market Intelligence

1 · Executive dashboard

Wait for evidence

Regime call: nearly flat U.S. futures and a low-but-rising VIX are offset by WTI above $82, the U.S. 10Y at 4.72%, safe-haven gold near records, and Wednesday CPI. Monday's quiet index decline concealed sharper reversals in high-beta AI and quantum. Inference: this is not broad risk-off, but the reward for pre-event chasing has deteriorated; preserve optionality.

S&P 5007,753.11−0.06% Mon

Nasdaq Composite26,605.36−0.32%

Dow Jones53,975.98−0.11%

Russell 20003,017.40−0.56%

VIX15.46+3.76%

U.S. 2Y4.25%Official Mon

U.S. 10Y4.72%+7 bp vs Fri

DXY proxy99.84+0.03%

WTI Sep.$82.68+0.67% live

Gold Dec.$4,429+1.55% live

Market	Latest	Move	Session / interpretation
S&P / Nasdaq futures	7,778 / 29,786	+0.02% / +0.16%	Yahoo 06:00 UTC bars; Reuters cross-check +0.10% / +0.28%
Dow / Russell futures	54,025 / 3,027	−0.07% / +0.07%	Essentially flat pre-CPI
Nikkei 225	66,970	+2.08%	Aug. 10 latest; Japan holiday limits Tuesday cash/rates signal
Hang Seng	25,716	−0.85%	Live near cutoff
Shanghai Composite	3,947	−0.50%	Live near cutoff
Kospi / Taiwan	6,362 / 45,121	+0.99% / +0.43%	Latest Tuesday bars; regional picture mixed
Euro STOXX 50 / DAX futures	—	−0.05% / flat	Reuters pre-open indication; no false precision
FTSE futures	—	Flat	Reuters pre-open indication

1 · Hormuz is the macro transmission channel

Confirmed: Reuters put Brent at $88 and WTI at $82.45 after Monday's roughly 5% rally as U.S.–Iran negotiations stalled. Shipping traffic fell to six vessels versus a 10-day average near 11. Inference: oil now directly threatens Wednesday's inflation/rates relief thesis.

2 · CPI carries asymmetric risk

BLS confirms July CPI Wednesday at 08:30 ET. Reuters' current reference is +0.1% headline and +0.2% core m/m. Cleveland Fed President Hammack argued for gradual hikes. A hot print would likely pressure duration-sensitive AI/quantum.

3 · AI financing shifts the question

Reuters reports NVIDIA and six financial institutions launched platforms targeting over $500B of third-party AI-infrastructure capital. Demand access is bullish; the need to financialize compute raises leverage, utilization and credit-quality questions.

2 · Market-moving analysis

Facts separated from inference

Confirmed macro, rates & liquidity

Monday's S&P slipped 0.06%; Russell underperformed at −0.56%, while VIX rose to 15.46. This is mild de-risking, not capitulation.
Official Treasury closes moved to 4.25% (2Y) and 4.72% (10Y), versus 4.19%/4.65% Friday. Tuesday Asian Treasury cash trading was closed for Japan's holiday; futures implied slightly higher yields.
Reuters described September hike odds as roughly a coin toss. That market probability is volatile, not a forecast.
Today's U.S. calendar is light: existing-home sales at 10:00 ET and NY Fed consumer-credit data at 11:00 ET. A 3-year Treasury auction adds duration supply later.

Earnings, guidance & regulation

Tonight: CoreWeave and Super Micro both confirmed 17:00 ET calls. CoreWeave's outlook, capex, backlog conversion and financing matter more than headline revenue growth.
Super Micro's July 21 preliminary update put revenue near the low end of $11.0–12.5B guidance, but gross margin at 15–17% versus prior 8.2–8.4%; it cited >$60B Q4 orders while warning some may be cancellable/delayed. The board is independently reviewing transactions tied to alleged export-control issues.
Inference: the AI stack remains structurally strong, but today's events test whether financing and orders convert into cash and durable margin.
No material, directly verified new peptide-drug regulatory decision was found before cutoff; do not infer one from generic FDA calendars.

Geopolitics High

Washington and Tehran exchanged demands; reopening Hormuz is not imminent. Oil, freight and insurance are the market channels. A verified de-escalation would quickly reverse part of the risk premium.

Rotation Narrow

Monday: MSFT +1.21%, ANET +1.51% and LLY +3.90%, versus NVDA/AMD −2.86% and quantum pure plays −1.6% to −4.3%. Quality and earnings delivery beat broad thematic beta.

Unusual move filter Verified

LLY closed at its session high, +3.90%. NVDA closed near its low, −2.86% on 115.5M shares. These are price/volume facts; neither proves Tuesday direction.

3 · Thematic dashboards

AI infrastructure Event cluster

Monday leaders: ANET +1.51%, MSFT +1.21%, SMCI +1.06%. Laggards: NVDA and AMD −2.86%, CRWV −2.74%.
Verified catalysts: CRWV/SMCI Aug. 11, Cisco Aug. 12, Applied Materials Aug. 13, NVIDIA Aug. 26.
New development: reported >$500B compute-financing initiative broadens access to capital, but may move AI risk from capex budgets into credit structures.
Risk: utilization, customer concentration, leverage, power/cooling, export controls, margins and elevated expectations.

Quantum computing Speculative

Monday: IONQ −4.28%, QBTS −2.75%, RGTI −1.62%; five-day returns remain +9.47%, +1.05%, +10.17% respectively.
IONQ facts: Q2 revenue $80.1M (+287%), FY guide $280–290M; adjusted EBITDA loss $120.3M; pro-forma post-SkyWater liquidity $2.0B.
RGTI facts: Q2 revenue $5.1M versus $28.1M operating loss; $541.3M liquidity/no debt. The up-to-$100M Commerce item is an LOI contemplating government equity.
Valuation/speculation: revenue bases remain small versus market values; roadmap, contract timing, dilution and squeeze dominate. Avoid-chasing remains preferable to an unverified short.

Peptide / metabolic biotech Relative leader

Monday: LLY +3.90% to $1,231.94; VKTX +0.53%; NVO ADR +0.99%. LLY led the focused group.
LLY verified: Q2 revenue $23.0B (+48%); Mounjaro +91%, Zepbound +46%; FY revenue guide $85–87B. Volume +60% was partly offset by realized price −13%.
VKTX verified: Phase 3 VANQUISH trials fully enrolled; maintenance-dosing data expected in Q3; oral VK2735 Phase 3 initiation targeted Q4. Q2 cash/investments $502M versus $128M quarterly net loss.
Risk: premium multiples, realized-price pressure, reimbursement, manufacturing, competition, GI/safety, clinical/regulatory binary outcomes and cash burn.

4 · Ranked ideas

Conditional paper-tracking; fewer is better

#1 LLY · Eli Lilly Bullish on confirmation

NYSE · mega-cap · profitable peptide/metabolic leader · premium-valuation, policy and pipeline risk

Day trade: pullback/hold only1–4 weeks: applicable after CPI3–12+ months: applicable

Direction / thesis: may continue relative leadership because verified incretin volume, raised guidance and pipeline breadth are stronger evidence than thematic narrative alone.

Catalyst / evidence: Q2 revenue +48%, Mounjaro +91%, Zepbound +46%; Monday +3.90% and closed at $1,231.94 session high.

Counterargument: realized price fell 13%; the premium multiple leaves sensitivity to reimbursement, safety, competition and manufacturing execution.

Entry / confirmation: hold $1,220 after the open or a controlled retest of $1,196–1,200; avoid a CPI-gap chase.

Invalidation / downside: close below $1,184 Monday low, estimate cuts, access deterioration, safety signal or manufacturing shortfall.

Key risks: policy/pricing, Novo and emerging competitors, trial/regulatory outcomes, concentration and valuation compression.

Confidence

Risk

Opportunity

#2 RGTI · Rigetti Avoid chasing · not a short

Nasdaq · speculative small/mid-cap · quantum hardware · extreme volatility, dilution and squeeze risk

Day trade: avoid1–4 weeks: no clean edge3–12+ months: milestone watch

Direction / thesis: uncertain; $5.1M quarterly revenue and $28.1M operating loss do not support chasing a still-strong five-day rebound.

Catalyst / evidence: 108-qubit roadmap, deployments, HPE collaboration and Commerce LOI; $541.3M liquidity/no debt extends runway.

Counterargument: strategic government interest and technical milestones can sustain a premium and trigger sharp squeezes.

Confirmation: reconsider only after funded recurring awards, commercial conversion and improved economics; no borrow claim is made.

Invalidation / downside: avoid view weakens on large recurring wins; long downside accelerates below $17.48 then $16.40.

Key risks: tiny/lumpy revenue, roadmap execution, equity-linked funding, dilution and extreme beta.

Confidence

Risk

Opportunity

#3 IONQ · IonQ Avoid at price · not a short

NYSE · speculative mid-cap · full-stack quantum/foundry · M&A, loss, dilution and squeeze risk

Day trade: avoid volatility1–4 weeks: wait for base3–12+ months: conversion watch

Direction / thesis: high growth is confirmed, but loss intensity, acquisition complexity and valuation make risk/reward weak without operating leverage.

Catalyst / evidence: Q2 revenue +287%, raised $280–290M guide and broad platform; adjusted EBITDA loss $120.3M.

Counterargument: $2.0B pro-forma liquidity, commercial/international mix and vertical integration could support strategic value.

Confirmation: recurring revenue conversion, durable gross margin and narrowing burn; technical stabilization above $44.20.

Invalidation / downside: avoid view changes on verified margin inflection; price downside levels $42.20 then recent base near $40.

Key risks: procurement timing, roadmap, SkyWater integration, dilution/warrants and squeeze; no borrow terms asserted.

Confidence

Risk

Opportunity

Watchlist · five maximum

NVDA · NVIDIA Downgraded to watch

Nasdaq · mega-cap · AI compute/networking · C/R/O 76/68/65

Horizons: day trade only after reclaim; 1–4 weeks post-CPI; long-term applicable. Thesis/catalyst: AI financing and Aug. 26 earnings may validate growth, but Monday's breakout failed. Evidence/counter: −2.86%, close $217.55 near $216.77 low despite financing news; five-day +5.28%. Confirm: reclaim $224.14 with breadth. Invalidate/downside: close below $216.77; yields >4.72%, export/capex or demand shock. Risks: valuation, concentration, regulation, power and supply.

CRWV · CoreWeave Binary earnings watch

Nasdaq · high-risk AI cloud · leverage/concentration · C/R/O 61/89/59

Horizons: no pre-results day trade; 1–4 weeks after call; long term only with cash-flow proof. Catalyst: confirmed 17:00 ET Q2 call. Evidence/counter: $99.4B Q1 backlog versus financing, capex and concentration risk; Monday −2.74% to $88.19. Confirm: utilization, backlog conversion and funded free-cash path. Invalidate/downside: weak guide or break $88.17. Risks: debt, customers, GPUs, pricing and earnings gap.

SMCI · Super Micro High-risk event

Nasdaq · mid/large-cap AI systems · governance/export risk · C/R/O 70/88/63

Horizons: no pre-results trade; swing after 17:00 ET; investment only after review clarity. Thesis: 15–17% preliminary gross margin and >$60B orders may offset low-end revenue. Counter: orders may be cancellable/delayed; export-control transaction review. Confirm: audited-quality reconciliation, cash conversion and guide; above $33.39. Invalidate/downside: below $31.43 or adverse review. Risks: governance, customers, margins, export controls.

VKTX · Viking Therapeutics Biotech binary

Nasdaq · clinical-stage small/mid-cap · peptide/metabolic · C/R/O 73/91/66

Horizons: no day-trade edge; 1–4 week Q3-data watch; long term Phase 3. Thesis: maintenance-dosing readout and fully enrolled VANQUISH program offer catalysts. Counter: Phase 2 efficacy/safety may not replicate; $502M cash versus $128M Q2 loss creates financing risk. Confirm: statistically and clinically meaningful weight maintenance with tolerability, above $34.70. Invalidate/downside: safety/efficacy miss or below $33.80. Risks: binary trial, cash burn, competition, regulation/manufacturing.

MSFT · Microsoft Quality alternative

Nasdaq · mega-cap · cloud/AI + quantum optionality · C/R/O 75/55/68

Horizons: day trade after CPI only; 1–4 weeks and long term applicable. Thesis: diversified cash generation offers lower-risk AI/quantum exposure than pure plays. Evidence/counter: Monday +1.21% to $506.06, but AI capex returns and cloud competition remain. Confirm: hold $502.27 then reclaim $513.73. Invalidate/downside: close below $498 or deteriorating cloud/AI economics. Risks: valuation, capex, antitrust, competition.

5 · Changes since Aug. 10

Regime downgraded: risk-on/event-sensitive → neutral/event-risk elevated. Oil jumped ~5% Monday, 10Y reached 4.72%, VIX rose and Russell lagged.
NVDA removed from bullish rank: the required breakout above $224.76 did not confirm; Monday high was $224.14 and close $217.55. It did not quite trigger the prior close-below-$217 invalidation, but confidence and opportunity fell.
LLY strengthened: prior confirmation above $1,196.80 occurred; Monday closed +3.90% at the high. It becomes #1, but entry discipline tightens after the move.
Quantum avoid calls retained: RGTI −1.62% and IONQ −4.28% Monday. This supports avoid-chasing for one session, not a claim of predictive success or a short recommendation.
CRWV/SMCI: move from general watch to binary event watch with company-confirmed 17:00 ET calls. No position is initiated before results.
Completed catalyst: Monday's U.S. cash session invalidated the NVDA breakout setup; no other thesis invalidation occurred. Initial two-week paper tracking continues.

6 · Important 7–30 day catalysts

U.S. times ET unless stated; verify near event

Aug. 11 · 10:00 / 11:00 — Existing-home sales / NY Fed consumer credit

Secondary macro signals; 3-year Treasury auction later.

Aug. 11 · 17:00 — CoreWeave and Super Micro results

Company-confirmed. Financing, capex, backlog/orders, cash conversion, margins, customer concentration and export-control review.

Aug. 12 · 08:30 — July CPI and real earnings

BLS-confirmed. Primary cross-asset gate; Reuters expectation reference +0.1% headline, +0.2% core m/m.

Aug. 12 · after close — Cisco FY26 results

AI networking orders, enterprise demand, margins and outlook.

Aug. 13 · 08:30 / 16:30 — PPI + claims / Applied Materials call

Inflation pipeline; foundry/logic, memory, advanced packaging and export commentary.

Aug. 14 — Retail sales / Michigan sentiment

Consumption and inflation expectations after weak payrolls and higher oil.

Aug. 17–25 — FDA decision cluster outside core peptide focus

Third-party calendars flag multiple biotech actions; exact drug/company dates require issuer/FDA verification before trading. No focused peptide PDUFA asserted.

Aug. 19 · 14:00 — FOMC minutes

Policy-division detail after three July dissents for a hike.

Aug. 26 · 14:00 PT — NVIDIA Q2 FY27 results

Company-confirmed. Compute/networking demand, supply, margins, financing and export controls.

Q3 2026 · date not fixed — Viking VK2735 maintenance-dosing data

Company guidance only; binary efficacy/tolerability event. Do not assume a date until IR confirms.

7 · Bottom line

Current session / day trade

No compelling pre-CPI trade. If LLY holds $1,220 after the open, it has the best relative-strength evidence; otherwise stay flat. Do not front-run CRWV/SMCI results.

1–4 week swing

LLY after CPI. Prefer a controlled hold/retest of $1,196–1,220 over chasing. Invalidate below $1,184 or on access/estimate deterioration.

3–12+ month investment

LLY first; MSFT as diversified watch. LLY has verified growth but premium risk. MSFT offers AI/quantum optionality with lower binary exposure than pure plays.

Biggest risk: a hot CPI while Hormuz remains constrained could push oil and yields higher together, compressing AI/quantum multiples and challenging consumer margins. Upgrade neutral→risk-on: benign CPI, WTI back below $80, 10Y below 4.65% and constructive CRWV/SMCI cash/margin evidence. Downgrade→risk-off: WTI >$85, 10Y >4.80%, S&P loses Monday's range with broad weakness, or major AI guidance disappoints.

Sources & data quality

Data-quality panel

U.S. cash values are Aug. 10 closes from Yahoo's chart endpoint and are cross-checked against Reuters for major indices. Yahoo bars timestamp daily instruments by session conventions; exact real-time quotes may differ.
Asian index values were latest Yahoo bars near 08:31 CEST; Hang Seng/Shanghai were live, while Nikkei's latest bar was Aug. 10 because of Japan's holiday. European markets were pre-open; Reuters futures direction is used without invented contract levels.
Yahoo futures/commodity values were 06:00 UTC daily-bar snapshots. Reuters values from its later Asian article provide a timestamped cross-check. Futures can move before delivery.
Official Treasury XML confirms Aug. 10 closes: 2Y 4.25%, 10Y 4.72%. VIX 15.46 and U.S. index values were independently consistent across Yahoo and Reuters.
Primary company sources succeeded for CoreWeave, Super Micro, IonQ, Rigetti, Lilly, Viking and NVIDIA's earnings date. The >$500B NVIDIA financing development is sourced to Reuters; a same-cutoff primary release was not retrieved, so wording remains “Reuters reports.”
Web search hit a per-minute rate limit on several queries, but retries via direct extraction and accessible primary IR/official sources succeeded for every material idea. Generic FDA calendars were not sufficient to assert a focused peptide catalyst.
Technical levels are Monday OHLC, not forecasts. Scores are analyst calibration: Confidence is evidence quality, Risk is higher when riskier, Opportunity is conditional—not probability of gain.